Cim, LLC Vertex Pharmaceuticals Inc Transaction History

Cim, LLC

$676 Million
Q2 2024

A detailed history of Cim, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cim, LLC holds 2,947 shares of VRTX stock, worth $1.38 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

2,947

Previous 2,905 1.45%

Holding current value

$1.38 Million

Previous $1.21 Million 13.76%

% of portfolio

0.2%

Previous 0.18%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Sep 06, 2024	BUY	$392.81 - $485.53 $16,498 - $20,392	42 Added 1.45%	2,947 $1.38 Million
Q1 2024 May 20, 2024	BUY	$407.69 - $446.08 $25,276 - $27,656	62 Added 2.18%	2,905 $1.21 Million
Q4 2023 Feb 23, 2024	BUY	$343.0 - $410.68 $71,687 - $85,832	209 Added 7.93%	2,843 $1.16 Million
Q3 2023 May 17, 2024	BUY	$338.18 - $362.46 $37,537 - $40,233	111 Added 4.22%	2,742 $953,000
Q2 2023 May 17, 2024	SELL	$314.42 - $351.91 $66,657 - $74,604	-212 Reduced 7.46%	2,631 $925,000
Q1 2023 May 17, 2024	SELL	$283.23 - $323.1 $60,044 - $68,497	-212 Reduced 7.46%	2,631 $828,000
Q4 2022 Feb 10, 2023	SELL	$285.76 - $321.48 $9,715 - $10,930	-34 Reduced 1.27%	2,634 $760,000
Q3 2022 Nov 02, 2022	SELL	$273.83 - $305.53 $141,570 - $157,959	-517 Reduced 16.23%	2,668 $838,000
Q2 2022 Jul 11, 2022	SELL	$234.96 - $292.55 $29,370 - $36,568	-125 Reduced 3.78%	3,185 $937,000
Q1 2022 Apr 12, 2022	BUY	$221.42 - $260.97 $732,900 - $863,810	3,310 New	3,310 $930,000
Q3 2020 Nov 06, 2020	SELL	$255.65 - $303.1 $642,192 - $761,387	-2,512 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$225.48 - $295.8 $577,228 - $757,248	-2,560 Closed	0 $0
Q1 2020 May 05, 2020	BUY	$199.77 - $247.81 $511,411 - $634,393	2,560 New	2,560 $609,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cim, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cim, LLC with notifications on news.

Account